USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
PHARMAIN CORPORATION
Address:
19805 N. Creek Pkwy, Suite 200
Bothell, WA
Phone:
N/A
URL:
EIN:
136435786
DUNS:
167580682
Number of Employees:
5
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $4,383,699.00 9
SBIR Phase II $5,161,388.00 3

Award List:

Targeted formulations of GLP -1 for Type 1 diabetes

Award Year / Program / Phase:
2004 / SBIR / Phase I
Award Amount:
$1,000,599.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): New therapies are desperately needed for patients with Type 1 diabetes. Recent reports that the insulin-stimulating hormone Glucagon-Like Peptide (GLP-1), can increase pancreatic beta cell mass, offers the exciting prospect that beta cells can be regenerated… More

Long Acting Native GLP-1 formulations for Type 1 Diabetes

Award Year / Program / Phase:
2007 / SBIR / Phase II
Award Amount:
$2,834,814.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): New therapies are desperately needed to relieve patients with Type 1 diabetes from the neuropathy, nephropathy and retinopathy associated with the current standard of treatment, injected insulin. The recent finding that islet cells can be regenerated in diabetic… More

Nanocarrier with metal bridge for affinity based delivery of metal binding peptid

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$383,625.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Lysostaphin, a metalloendopeptidase that is bacteriolytic for Staphylococcus aureus, is a potential systemic therapy for treating multidrug-resistant S. aureus mediated infections. However, the short half life of this e nzyme in vivo has precluded its development… More

EGF/Gastrin for islet cell regeneration

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$443,608.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): New therapies are desperately needed to relieve patients with Type 1 diabetes from the neuropathy, nephropathy and retinopathy associated with the current standard of treatment, injected insulin. Transplantation of panc reatic islet cells in combination with… More

Long-acting VIP formulations for the treatment of chronic inflammatory diseases

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$600,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Despite the success of TNF-inhibitors and other new biological drugs for the treatment of autoimmune and other chronic inflammatory diseases, there are still many patients that are only poorly controlled. Vasoactive int estinal peptide (VIP) is an… More

Nanocarrier-formulated anti-fibrotic peptides for cirrhosis - Fast Track SBIR

Award Year / Program / Phase:
2010 / SBIR / Phase II
Award Amount:
$782,928.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): This application pertains to the development of Medication for Hepatic Fibrosis. Established cirrhosis has a 10-year mortality of 34-66%, largely dependent on the cause of the cirrhosis; alcoholic cirrhosis has a worse prognosis than primary biliary cirrhosis and… More

Outpatient treatment for portal hypertension

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$223,422.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Portal hypertension (increased pressure in the portal venous system) is one of the main consequences of cirrhosis. Although the reduction of portal hypertension is well documented to prevent the development of life-thre atening consequences, including bleeding… More

Nanocarrier-formulated anti-fibrotic peptides for cirrhosis - Fast Track SBIR

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$160,363.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): This application pertains to the development of Medication for Hepatic Fibrosis. Established cirrhosis has a 10-year mortality of 34-66%, largely dependent on the cause of the cirrhosis; alcoholic cirrhosis has a worse prognosis than primary biliary cirrhosis… More

Nanocarrier-formulated NF-kB inhibitors for Inflammatory diseases

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$599,949.00
Agency:
HHS
Principal Investigator:
Gerardo M. Castillo – 206-568-1499
Abstract:
DESCRIPTION (provided by applicant): Despite the success of TNF-inhibitors and other new biological drugs for the treatment of autoimmune and other chronic inflammatory diseases, there are still many patients that respond poorly. Suppressing NF-kB induction as treatment of chronic inflammatory… More

Nanocarrier formulated enzyme for the treatment of S. aureus infection

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$600,000.00
Agency:
HHS
Principal Investigator:
Gerardo M. Castillo – 206-568-1499
Abstract:
DESCRIPTION (provided by applicant): Lyso, a metalloendopeptidase that is bacteriolytic for S. aureus, is a potential systemic therapy for treating methicillin-resistant S. aureus (MRSA) mediated infections including endocarditis, osteomyelitis, catheter related infections, and MRSA-mediated… More

Vasoactive intestinal peptide for the treatment of psoriasis

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$372,133.00
Agency:
HHS
Principal Investigator:
Sandra Reichstetter – 206-568-1450
Abstract:
DESCRIPTION (provided by applicant): Psoriasis is a chronic inflammatory skin disease that to this date is only insufficiently controlled by currently available treatments which can also come with severe, and sometimes life threatening side effects. In this application, we propose to create a new… More

EGF/Gastrin for Islet Regeneration

Award Year / Program / Phase:
2013 / SBIR / Phase II
Award Amount:
$1,543,646.00
Agency:
HHS
Principal Investigator:
Gerardo M. Castillo – 206-568-1499
Abstract:
DESCRIPTION (provided by applicant): New therapies are desperately needed to relieve patients with Type 1 diabetes from the neuropathy, nephropathy and retinopathy associated with the current standard of treatment, injected insulin. Transplantation of pancreatic islet -cells, in combination with… More